Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer.

Irinotecan (CPT-11) is a widely used potent antitumor drug that inhibits mammalian DNA topoisomerase I (Topo I). However, overexpression of ABCG2 (BCRP/MXR/ABCP) reportedly confers cancer cells resistance to SN-38, the active form of CPT-11. To circumvent the ABCG2-associated drug resistance, the structure-activity-relationship (SAR) of 14 new camptothecin (CPT) analogues has been studied with respect to the substrate specificity of ABCG2. While the lactone E ring is a prerequisite for anticancer activity, modifications of the A or B rings do not significantly affect Topo I inhibition. Based on the substrate specificity of ABCG2, it is strongly suggested that CPT analogues with a hydroxyl group at position 10 or 11 of the A ring are recognized by ABCG2 and are thereby effectively extruded from cancer cells. To develop a platform for the molecular modeling to circumvent anticancer drug resistance, we have carried out quantum chemical calculations and neural network SAR analysis. Electrostatic potential iso-surfaces generated by ab initio MO calculations using restricted Hartree-Fock method have revealed that negative potential localized at positions 10 or 11 in the A ring is important for recognition by ABCG2.

[1]  A. Klamt,et al.  COSMO : a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient , 1993 .

[2]  T. Langmann,et al.  Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization. , 2004, Biochemical and biophysical research communications.

[3]  A. Schinkel,et al.  Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). , 2002, Molecular cancer therapeutics.

[4]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[5]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[6]  Peter J Houghton,et al.  Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice , 2004, Cancer Research.

[7]  J. Verweij,et al.  O6‐Methylguanine‐DNA Methyltransferase (MGMT) as a Determinant of Resistance to Camptothecin Derivatives , 2002, Japanese journal of cancer research : Gann.

[8]  T. Ishikawa,et al.  Novel camptothecin analogues that circumvent ABCG2‐associated drug resistance in human tumor cells , 2004, International journal of cancer.

[9]  H. McLeod,et al.  ABCG2 Pharmacogenetics , 2004, Clinical Cancer Research.

[10]  U Schaeppi,et al.  Toxicity of camptothecin (NSC-100880). , 1974, Cancer chemotherapy reports. Part 3.

[11]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Hertzberg,et al.  On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. , 1989, Biochemistry.

[13]  Y. Suzuki,et al.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Kohn,et al.  How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair? , 2007, Cell Biochemistry and Biophysics.

[15]  P. Borst,et al.  Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.

[16]  S. Rabindran,et al.  Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. , 1998, Cancer research.

[17]  K. Yamaguchi,et al.  Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. , 1991, Chemical & pharmaceutical bulletin.

[18]  L. Liu,et al.  The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. , 1992, Cancer research.

[19]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[20]  S. Shumway,et al.  NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. , 2000, The Journal of biological chemistry.

[21]  P. D'Arpa,et al.  Mechanism of Action of Camptothecin , 1996, Annals of the New York Academy of Sciences.

[22]  K. Kohn,et al.  Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes , 1999, The EMBO journal.

[23]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[24]  K. Sharp,et al.  Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .

[25]  A. Guarino,et al.  Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). , 1970, Cancer chemotherapy reports.

[26]  L. Schmitt,et al.  CHAPTER 11 – BACTERIAL ABC TRANSPORTERS INVOLVED IN PROTEIN TRANSLOCATION , 2003 .

[27]  B. Sarkadi,et al.  An inventory of the human ABC proteins. , 1999, Biochimica et biophysica acta.

[28]  J. Svejstrup,et al.  New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. , 1991, Journal of molecular biology.

[29]  K. Ono,et al.  An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. , 1999, Cancer letters.

[30]  T. Langmann,et al.  Role of ABCG1 and other ABCG family members in lipid metabolism. , 2001, Journal of lipid research.

[31]  L. Doyle,et al.  Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. , 2001, Biochemical and biophysical research communications.

[32]  David Neil Cooper,et al.  Nature encyclopedia of the human genome , 2003 .

[33]  Y. Fujiwara,et al.  The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro , 1997, Japanese journal of cancer research : Gann.

[34]  S. Nishimura,et al.  ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. , 2002, Biochemical and biophysical research communications.

[35]  J. Champoux,et al.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.

[36]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[37]  J. Schellens,et al.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.

[38]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[39]  L. Liu,et al.  Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. , 1993, Cancer research.

[40]  M. Horwitz,et al.  Effects of camptothecin on the breakage and repair of DNA during the cell cycle. , 1973, Cancer research.

[41]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[42]  T. Tanaka,et al.  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. , 1987, Cancer research.

[43]  T. Ishikawa,et al.  Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. , 2004, Journal of experimental therapeutics & oncology.

[44]  W. Dalton,et al.  Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. , 1999, Cancer research.

[45]  L. Liu,et al.  DNA topoisomerases: essential enzymes and lethal targets. , 1994, Annual review of pharmacology and toxicology.

[46]  C. Guillemette,et al.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.

[47]  M. Redinbo,et al.  Structural insights into CPT-11 activation by mammalian carboxylesterases , 2002, Nature Structural Biology.

[48]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[49]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[50]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .

[51]  L. Doyle,et al.  Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. , 2001, Biochimica et biophysica acta.

[52]  Karl Kuchler,et al.  ABC proteins : from bacteria to man , 2003 .

[53]  T. Ishikawa,et al.  Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. , 2001, Biochemical and biophysical research communications.

[54]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Y. Pommier,et al.  Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. , 1999, Cancer research.

[56]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[57]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[58]  T. Furuta,et al.  Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. , 1990, Cancer research.

[59]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[60]  M Dietel,et al.  Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. , 1999, Journal of the National Cancer Institute.

[61]  V. Ling.  Multidrug resistance: molecular mechanisms and clinical relevance , 1997, Cancer Chemotherapy and Pharmacology.

[62]  J. Piette,et al.  Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. , 1996, Nucleic acids research.